Imagine a smart bandage that fights germs without using expensive silver. It uses tiny, self-assembling structures to heal deep wounds and burns more effectively. This technology acts like a protective shield that keeps infections away while helping the skin repair itself.
Chronic wounds and burns are expensive to treat and prone to infection. Current silver-based treatments are costly and present environmental and safety concerns.
The project is developing up to 5 multifunctional nanostructured biomaterials, including 3D molecular materials and nanovesicles, to replace silver in wound dressings.
If you are a dressing manufacturer dealing with the high cost and safety concerns of silver-based products — this project developed multifunctional biomaterials that provide an affordable alternative for treating complex wounds. This allows for a more cost-effective product line for chronic wound management.
If you are a drug developer dealing with biofilm formation in chronic wounds — this project developed nanovesicles and bioactive molecules that improve the delivery of antimicrobial agents. This increases the efficacy of treatments for the 2% of the population in developed countries affected by complex wounds.
If you are a production plant dealing with expensive manufacturing processes for medical materials — this project developed green manufacturing and scale-up techniques for 3D molecular materials. This enables the production of high-tech dressings using affordable EU-based technologies.
The project aims to replace expensive silver-based products with affordable EU-based manufacturing technologies to reduce the economic impact of complex wound care.
The project specifically includes 'green manufacturing' and 'scale-up' as keywords and aims to use affordable manufacturing technologies to produce at least two innovative biomaterials.
Based on available project data, the project is currently in the development and testing phase (TRL 3 to TRL 5), and specific licensing terms are not yet disclosed.
The project includes partners with expertise in regulatory affairs and aims to move materials from proof-of-concept to the preclinical regulatory stage (TRL 5).
The project runs from 2023-01-01 to 2026-12-31, with in vivo testing for at least two materials expected in 2025.
The consortium is well-balanced for commercialization, featuring a 33% industry ratio with 5 SMEs and 9 academic/research institutions. This mix ensures that high-level nanotechnology research from 7 countries is directly linked to 5 commercial entities capable of scaling and marketing the resulting wound-healing products.
Contact the Consorcio Centro de Investigacion Biomedica en Red M.P. in Spain
Contact us to explore licensing opportunities for silver-alternative antimicrobial biomaterials.
